Clinical trial
Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
NCT00420732 · NewLink Genetics Corporation, Industry · Terminated
Key facts
| NCT number | NCT00420732 |
|---|---|
| Title | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Biological |
| Interventions | HyperAcute-Lung Cancer Vaccine |
| Enrollment | 6 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Dec 1, 2014 |
| First posted | Jan 11, 2007 |
| Last update posted | May 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: